Pro- and prebiotic effects on oxidative stress and inflammatory markers in non-alcoholic fatty liver disease

Asia Pacific Journal of Clinical Nutrition

Volumn 27, Issue 5, 2018, Pages 1031-1039

  Javadi, Leila ^a   Khoshbaten, Manouchehr ^b   Safaiyan, Abdolrasoul ^c   Ghavami, Mostafa ^d   Abbasi, Mehran Mesgari ^e   Gargari, Bahram Pourghassem ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NONE   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Inflammatory markers; Liver diseases; Oxidative stress; Prebiotic; Probiotic

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PREBIOTIC AGENT; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; BIFIDOBACTERIUM LONGUM; BLOOD; BODY MASS; BODY WEIGHT; COMPLICATION; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; LACTOBACILLUS ACIDOPHILUS; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; WAIST CIRCUMFERENCE;

ADULT; ANTIOXIDANTS; BIFIDOBACTERIUM LONGUM; BIOMARKERS; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; LACTOBACILLUS ACIDOPHILUS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PREBIOTICS; PROBIOTICS; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE;

EID: 85054608740     PISSN: 09647058     EISSN: None     Source Type: Journal    
DOI: 10.6133/apjcn.042018.05     Document Type: Article

References (43)

1. Oldfield IV, Dong RZ, Johnson DA. Non-alcoholic fatty liver disease and the gut microbiota: exploring the connection. J Gastrointest Dig Syst. 2014;4:245
2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep. 28431
3. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59-69. doi: 10.1016/j.freerad biomed.2011.10.003
4. Zhang W, Kudo H, Kawai K, Fujisaka S, Usui I, Sugiyama T, Tsukada K, Chen N, Takahara T. Tumor necrosis factor alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. Biochem Biophys Res Commun. 2010;391:1731-6. doi: 10.1016/j. bbrc.2009.12.144
5. Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015;7:2962-7. doi: 10.4254/wjh.v7.i30.2962
6. Moschen AR, Kaser S, Tilg H. Non-alcoholic steatohepatitis: a microbiota driven disease. Trends Endocrinol Metab. 2013;24:537-45. doi: 10.1016/j.tem.2013.05.009
7. Duseja A, Chawla YK. Obesity and NAFLD: the role of bacteria and microbiota. Clin Liver Dis. 2014;18:59-71. doi: 10.1016/j.cld.2013.09.002
8. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut micro-biota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. doi: 10.1038/srep08096
9. Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, PlazaDiaz J, Gil A. Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and nonalcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci. 2016;17:pii:E928. doi: 10.3390/ijms 17060928
10. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J Environ Res Public Health. 2014;11:4745-67. doi: 10.3390/ijerph110504745
11. Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013; 23:518-26
12. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015;2015:505878. doi: 10.1155/2015/505878
13. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401-12
14. Slavin J. Fiber and prebiotics: mechanisms and health benefits. Nutrients. 2013;5:1417-35. doi: 10.3390/nu50414 17
15. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of nonalcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012;32:701-11. doi: 10.1111/j. 1478-3231.2011.02730.x
16. Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7: 559-65. doi: 10.4254/wjh.v7.i3.559
17. Tarantino G, Finelli C. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. Future Microbio. 2015;10: 889-902. doi: 10.2217/fmb.15.13
18. Reid G, Food and Agricultural Organization of the United Nation and the WHO. The importance of guidelines in the development and application of probiotics. Curr Pharm Des. 2005;11:11-6
19. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:6821-5. doi: 10.3748/wjg.v20.i22. 6821
20. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R et al. Bifidobacterium longum with fructooligosaccharides in patients with non-alcoholic steatohepatitis. Dig Dis Sci. 2012; 57:545-53. doi: 10. 1007/s10620-011-1887-4
21. Marfell-Jones MJ, Stewart AD, de Ridder JH. International standards for anthropometric assessment. Wellington, New Zealand: International Society for the Advancement of Kinan-thropometry ; 2012
22. Javadi L, Ghavami M, Khoshbaten M, Safaiyan A, Barzegari A, Pourghassem Gargari B. The effect of probiotic and/or prebiotic on liver function tests in patients with nonalcoholic fatty liver disease: A double blind randomized clinical trial. Iran Red Crescent Med J. 2017; 19:e46017. doi: 10.5812/ircmj.46017
23. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2014;39:1276-85. doi: 10.1111/apt.12758
24. Yadav H, Lee JH, Lloyd J, Walter P, Rane SG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;30:25088-97. doi: 10. 1074/jbc.M113.452516
25. Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis. Nutrients. 2016;8:pii:E397. doi: 10.3390/nu8070397
26. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver dis-ease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011;15:1090-5
27. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, doubleblind, placebo-controlled pilot study. Am J Clin Nutr. 2014; 99: 535-42. doi: 10.3945/ajcn.113.068890
28. Torres-Fuentes C, Schellekens H, Dinan TG, Cryan JF. A natural solution for obesity: bio-actives for the prevention and treatment of weight gain. A review. Nutr Neurosci. 2015;18:49-65. doi: 10.1179/1476830513Y.0000000099
29. Verhoef SP, Meyer D, Westerterp KR. Effects of oligofructose on appetite profile, glucagon-like peptide 1 and peptide YY3-36 concentrations and energy intake. Br J Nutr. 2011;106:1757-62. doi: 10.1017/S0007114511002194
30. Parnell JA, Reimer RA. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am J Clin Nutr. 2009;89:1751-9. doi: 10.3945/ajcn.2009.27465
31. Akram Kooshki A, Tofighiyan T, Rakhshani MH. Effects of synbiotics on inflammatory markers in patients with type 2 diabetes mellitus. Glob J Health Sci. 2015;7:1-5. doi: 10. 5539/gjhs.v7n7p1
32. Asemi Z, Khorrami-Rad A, Alizadeh SA, Shakeri H, Esmaillzadeh A. Effects of synbiotic food consumption on metabolic status of diabetic patients: A double-blind randomized cross-over controlled clinical trial. Clin Nutr. 2014;33:198-203. doi: 10.1016/j.clnu.2013.05.015
33. Asgharian A, Askari G, Esmailzade A, Feizi A, Mohammadi V. The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease. Int J Prev Med. 2016;10:59. doi: 10.4103/2008-7802.178533
34. Gao X, Zhu Y, Wen Y, Liu G, Wan C. Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. Hepatol Res. 2016;46:1226-33. doi: 10.1111/hepr.12671
35. Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, Caropreso M, Val-lone G, Meli R. Effects of Lactobacillus rhamnosus strain GG in pediatric obesityrelated liver disease. J Pediatr Gastroenterol Nutr. 2011;52: 740-3. doi: 10.1097/MPG.0b013e31821f9b85
36. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'auria MV, De Simone C, Del Vec-chio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39:540-3
37. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Tarantino M, Scopacasa F, Vecchione R. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol. 2009;21:504-11. doi: 10.1097/MEG.0b013e3283229b40
38. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87. doi: 10.1002/hep.22848
39. Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, Vitetta L. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2016;9:463-72. doi: 10.1177/1756283X1664 5055
40. Ipar N, Aydogdu SD, Yildirim GK, Inal M, Gies I, Vandenplas Y, Dinleyici EC. Effects of synbiotic on anthropometry, lipid profile and oxidative stress in obese children. Benef Microbes. 2015;6:775-82. doi: 10.3920/ BM2015.0011
41. Borges Haubert NJ, Marchini JS, Carvalho Cunha SF, Suen VM, Padovan GJ, Jordao AA Junior, Marchini Alves CM, Marchini JF, Vannucchi H. Choline and fructooligosaccharide: non-alcoholic fatty liver disease, cardiac fat deposition, and oxidative stress markers. Nutr Metab Insights. 2015;4:1-6. doi: 10.4137/NMI.S24385
42. Pourghassem Gargari B, Dehghan P, Aliasgharzadeh A, Asghari Jafar-Abadi M. Effects of high performance inulin supplementation on glycemic control and antioxidant status in women with type 2 diabetes. Diabetes Metab J. 2013;37: 140-8. doi: 10.4093/dmj.2013.37.2.140
43. Kleniewska P, Hoffmann A, Pniewska E, Pawliczak R. The influence of probiotic Lactobacillus casei in combination with prebiotic inulin on the antioxidant capacity of human plasma. Oxid Med Cell Longev. 2016;2016:1340903. doi: 10.1155/2016/1340903